Current Report Filing (8-k)
September 27 2018 - 4:53PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
|
September
25, 2018
|
NOBILIS
HEALTH CORP.
(Exact
name of registrant as specified in its charter)
British
Columbia
|
|
001-37349
|
|
98-1188172
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
11700
Katy Freeway, Suite 300, Houston, Texas
|
|
77079
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
|
(713)
355-8614
|
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; APpointment of Certain OFFICERS; Compensatory ARRANGEMENTS of Certain
Officers
|
On
September 25, 2018, David Young tendered his resignation as the Chief Financial Officer of Nobilis Health Corp. (the “Company”),
such resignation to be effective on October 1, 2018. Mr. Young’s departure is not due to a dispute or disagreement
with the Company, its Board of Directors, its Audit Committee or its auditors or on any matter relating to the Company’s
operations, policies, practices or financial statements, including its controls or other financial related matters.
On
September 25, 2018, the Company appointed Ken Klein as the Company’s Interim Chief Financial Officer, effective immediately
following Mr. Young’s departure. As of that date, Mr. Klein will assume the duties of the Company’s principal financial
officer and principal accounting officer until such time as his successor is appointed, or until his earlier resignation or removal.
Mr.
Klein served as the Company’s Chief Financial Officer from 2007 to 2010 and again from July 2015 until February 2017. Prior
to joining the Company, Mr. Klein served for over five years as Senior Vice President, Chief Financial Officer and Treasurer of
the Menninger Clinic, one of the nation’s leading inpatient psychiatric hospitals. Mr. Klein has over 28 years of experience
in financial accounting & reporting, analysis, management, auditing, treasury and human resources, focusing primarily in the
health care, construction and financial services industries. Mr. Klein began his career in 1988 with KPMG Peat Marwick in the
audit practice. After KPMG, Mr. Klein has held various financial leadership positions with Texas Children’s Hospital, Memorial
Hermann Healthcare System, Thermo Fisher Scientific, and Castle Dental Centers. Mr. Klein graduated with a B.S. in accounting
from Sacred Heart University in Fairfield, Connecticut, where he was a member of Phi Beta Kappa and graduated with an M.B.A. and
Post Baccalaureate in Accounting from TWU in Houston Texas. Mr. Klein is a licensed CPA.
In
connection with Mr. Klein’s appointment as Chief Financial Officer, his annual base salary will be increased to $300,000.
A
copy of the Company’s press release, dated September 25, 2018, announcing the appointment of Mr. Klein as the Company’s
Interim Chief Financial Officer and the resignation of Mr. Young is attached hereto as Exhibit 99.1 and is incorporated herein
by reference.
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
NOBILIS
HEALTH CORP.
|
|
|
|
By:
|
/s/
Harry Fleming
|
|
|
Harry
Fleming
|
|
|
Chief
Executive Officer
|
|
|
|
|
Date: September 27, 2018
|
INDEX
TO EXHIBITS
Nobilis Health (AMEX:HLTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nobilis Health (AMEX:HLTH)
Historical Stock Chart
From Jul 2023 to Jul 2024